The global rheumatoid arthritis drugs market was valued at approximately USD 22.7 billion in 2018 and is expected to generate around USD 30.8 billion by 2026, at a CAGR of 4.8% between 2019 and 2026.
Rheumatoid arthritis (RA) is an autoimmune disorder that leads to pain and inflammation of the joints. It usually affects the joints of wrists, elbows, hands, ankles, and knees. The presence of biologics and biosimilars, the rising prevalence of the disease, and established regulatory guidelines are likely to boost the rheumatoid arthritis drugs market growth globally. Generally, RA affects twice the number of women as compared to men. The rising disease remittance therapies awareness and increasing healthcare expenditure in developed countries are likely to further promote rheumatoid arthritis drugs market growth globally in the future.
Rheumatoid arthritis (RA) is a chronic auto-immune disorder that majorly affects joints along with articular tissues and extraarticular organs. The disease is often progressive and results in pain, stiffness, and swelling of joints. Approximately 1% of the global population is affected by RA. It mostly onsets during middle ages, and women are affected 2.5 times as frequently as men. As there is no permanent cure for RA, the goals of the treatment are to reduce pain, decrease inflammation, prevent bone deformity, and improve a person’s overall function. This may be achieved through exercise and use of assistive devices, along with pain medication, steroids, and NSAIDs that are frequently used to help with the symptoms. To slow down the progression of disease, disease-modifying antirheumatic drugs (DMARDs) may be used. These drugs are the primary treatment for RA and have been found to improve symptoms, decrease joint damage, and improve overall functional abilities. However, early diagnosis and early treatment is the key for better management of the disease. Recent advancements with biosimilars which may be used to treat RA and increase in approvals of the same by regulatory affairs have opened new avenues for the RA drugs market.
The major factors that fuel the growth of the global rheumatoid arthritis drugs market include rise in incidence of rheumatoid arthritis and upsurge in geriatric population. In addition, transition from symptom management to slowing the progression of the disease further drives the market growth. However, side effects associated with the medication and higher cost of biologics & biosimilars restrain the growth of rheumatoid arthritis drug market. On the contrary, developments in the field of biosimilars and novel biologics are anticipated to offer profitable opportunities for the growth of the RA drugs market.
The market is segmented on the basis of therapeutic molecule, route of administration, sales channel, and region. Based on therapeutic molecule, the market is bifurcated into pharmaceuticals and biopharmaceuticals. The pharmaceuticals segment is further divided into include NSAIDs, analgesics, DMARDs, and corticosteroids. Biopharmaceuticals is sub segmented into biologics and biosimilars. Depending on route of administration, the market is classified into oral and parenteral. As per sales channel, it is divided into prescription and over-the-counter (OTC). Region wise, it is studied across North America, Europe, Asia-Pacific, and LAMEA.
The report provides a comprehensive analysis of the key players operating in global RA drug market players such as AbbVie Inc., Boehringer Ingelheim GmbH, Novartis AG, Regeneron Pharmaceuticals, Inc., Pfizer, Inc., Johnson & Johnsons Services, Inc, Bristol-Myers Squibb Company, F. Hoffmann-La Roche Ltd., Celegene Corporations, MedImmune, LLC, and Amgen Inc. Other players in the value chain includes Takeda Pharmaceutical Company Ltd., Biogen Inc., Celltrion Inc., and others.
Segmentation:
By Therapeutic Molecule
By Route of Administration
By Sales Channel
By Region
CHAPTER 1 INTRODUCTION
1.1. REPORT DESCRIPTION
1.2. KEY BENEFITS
1.3. KEY MARKET SEGMENTS
1.4. RESEARCH METHODOLOGY
1.4.1. Secondary research
1.4.2. Primary research
1.4.3. Analyst tools & models
CHAPTER 2 EXECUTIVE SUMMARY
2.1. CXO PERSPECTIVE
CHAPTER 3 MARKET OVERVIEW
3.1. MARKET DEFINITION AND SCOPE
3.2. KEY FINDINGS
3.2.1. Top investment pockets
3.2.2. Top winning strategies
3.3. MARKET SHARE ANALYSIS/TOP PLAYER POSITIONING, 2016
3.4. PORTER’S FIVE FORCES ANALYSIS
3.5. MARKET DYNAMICS
3.5.1. Drivers
3.5.2. Restraints
3.5.3. Opportunities
CHAPTER 4 GLOBAL RHEUMATOID ARTHRITIS (RA) DRUGS MARKET, BY DRUG CLASS
4.1. OVERVIEW
4.1.1. Market size and forecast
4.2. DISEASE-MODIFYING ANTI-RHEUMATIC DRUGS (DMARDS)
4.2.1. Key market trends
4.2.2. Growth factors and opportunities
4.2.3. Market size and forecast
4.3. NON-STEROIDAL ANTI- INFLAMMATORY DRUGS (NSAIDS)
4.3.1. Key market trends
4.3.2. Growth factors and opportunities
4.3.3. Market size and forecast
4.4. CORTICOSTEROIDS
4.4.1. Key market trends
4.4.2. Growth factors and opportunities
4.4.3. Market size and forecast
4.5. ANALGESICS
4.5.1. Key market trends
4.5.2. Growth factors and opportunities
4.5.3. Market size and forecast
CHAPTER 5 GLOBAL RHEUMATOID ARTHRITIS (RA) DRUGS MARKET, BY ROUTE OF ADMINISTRATION
5.1. OVERVIEW
5.1.1. Market size and forecast
5.2. ORAL
5.2.1. Market size and forecast
5.3. PARENTERAL
5.3.1. Market size and forecast
CHAPTER 6 GLOBAL RHEUMATOID ARTHRITIS (RA) DRUGS MARKET, BY REGION
6.1. OVERVIEW
6.2. NORTH AMERICA
6.2.1. Key market trends
6.2.2. Key growth factors and opportunities
6.2.3. Market size and forecast
6.2.3.1. U.S. market size and forecast
6.2.3.2. Canada market size and forecast
6.2.3.3. Mexico market size and forecast
6.2.4. North America Rheumatoid Arthritis (RA) Drugs Market by Drug Class
6.2.5. North America Rheumatoid Arthritis (RA) Drugs Market by Route of Administration
6.3. EUROPE
6.3.1. Key market trends
6.3.2. Key growth factors and opportunities
6.3.3. Market size and forecast
6.3.3.1. Germany market size and forecast
6.3.3.2. France market size and forecast
6.3.3.3. UK market size and forecast
6.3.3.4. Italy market size and forecast
6.3.3.5. Spain market size and forecast
6.3.3.6. Rest of Europe market size and forecast
6.3.4. Europe Rheumatoid Arthritis (RA) Drugs Market by Drug Class
6.3.5. Europe Rheumatoid Arthritis (RA) Drugs Market by Route of Administration
6.4. ASIA-PACIFIC
6.4.1. Key market trends
6.4.2. Key growth factors and opportunities
6.4.3. Market size and forecast
6.4.3.1. Japan market size and forecast
6.4.3.2. China market size and forecast
6.4.3.3. Australia market size and forecast
6.4.3.4. India market size and forecast
6.4.3.5. Rest of Asia-Pacific market size and forecast
6.4.4. Asia-Pacific Rheumatoid Arthritis (RA) Drugs Market by Drug Class
6.4.5. Asia-Pacific Rheumatoid Arthritis (RA) Drugs Market by Route of Administration
6.5. LAMEA
6.5.1. Key market trends
6.5.2. Key growth factors and opportunities
6.5.3. Market size and forecast
6.5.3.1. Brazil market size and forecast
6.5.3.2. Saudi Arabia market size and forecast
6.5.3.3. Argentina market size and forecast
6.5.3.4. South Africa market size and forecast
6.5.3.5. Rest of LAMEA market size and forecast
6.5.4. LAMEA Rheumatoid Arthritis (RA) Drugs Market by Drug Class
6.5.5. LAMEA Rheumatoid Arthritis (RA) Drugs Market by Route of Administration
CHAPTER 7 COMPANY PROFILES
7.1. ABBVIE
7.1.1. Operating business segments
7.1.2. Business performance
7.1.3. Key strategic moves and developments
7.2. BIOGEN, INC.
7.2.1. Operating business segments
7.2.2. Business performance
7.2.3. Key strategic moves and developments
7.3. BRISTOL-MYERS SQUIBB
7.3.1. Operating business segments
7.3.2. Business performance
7.3.3. Key strategic moves and developments
7.4. CELGENE CORPORATION
7.4.1. Operating business segments
7.4.2. Business performance
7.4.3. Key strategic moves and developments
7.5. CELLTRION INC.
7.5.1. Operating business segments
7.5.2. Business performance
7.5.3. Key strategic moves and developments
7.6. JOHNSON & JOHNSON
7.6.1. Operating business segments
7.6.2. Business performance
7.6.3. Key strategic moves and developments
7.7. MEDIMMUNE, LLC
7.7.1. Operating business segments
7.7.2. Business performance
7.7.3. Key strategic moves and developments
7.8. MERCK & CO., INC.
7.8.1. Operating business segments
7.8.2. Business performance
7.8.3. Key strategic moves and developments
7.9. NOVARTIS INTERNATIONAL AG
7.9.1. Operating business segments
7.9.2. Business performance
7.9.3. Key strategic moves and developments
7.10. TAKEDA PHARMACEUTICAL COMPANY LTD.
7.10.1. Operating business segments
7.10.2. Business performance
7.10.3. Key strategic moves and developments
Cross-segment Market Size and Analysis for
Mentioned Segments
Additional Company Profiles (Upto 5 With No Cost)
Additional Countries (Apart From Mentioned Countries)
Country/Region-specific Report
Go To Market Strategy
Region Specific Market DynamicsRegion Level Market Share Import Export AnalysisProduction AnalysisOthers